FGFR4 and hepatocellular carcinoma: Furthermore, molecular-targeted drugs for advanced HCC, including sorafenib, regorafenib, and lenvatinib, are categorized as multikinase inhibitors; FGFR4, a receptor for FGF19, is one of the most important therapeutic targets [43, 44].